CancerNetwork®
@CancerNetwrk
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.
You might like
📢 Calling all radiation oncologists! We’re launching a peer-reviewed, PubMed-indexed #radonc supplement in 2026, and are accepting submissions. ✨Introducing @brandonmancini of @bamfhealth and @UMich as our editor-at-large. 👉Find out how to submit and get published today:…
The key AEs from NALIRIFOX in NAPOLI 3 were GI- and hematologic-related, with favorable rates of neutropenia and less growth factor use vs nab-paclitaxel/gemcitabine in mPDAC. Click here for more from @DoctorDietrich: hubs.li/Q03VSZRf0 #pancsm #cancer #oncology
The KEYNOTE-B61 trial reports ORR 50.6% and DCR 82% with pembrolizumab + lenvatinib in previously untreated non–clear cell RCC—showing activity across chromophobe, papillary, and unclassified subtypes. Featuring Moshe Ornstein, MD, MA, of @ClevelandClinic, and Yasser Ged, MBBS,…
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent cancer care vs incarcerated patients with cancer. Watch more here: hubs.li/Q03VSW3q0 #oncology #cancer | @cpgYALE
🧬 Watch this Between the Lines series “Expert Perspectives on Novel Combination Therapy in Newly Diagnosed Myeloma” to explore how quadruplet regimens are redefining frontline care. In episode 1, experts highlight deeper, more durable responses with quad therapy vs traditional…
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025. Listen to more here: hubs.li/Q03VSWCd0 #lcsm #NSCLC #SCLC #oncology | @DrTomMarron
What is the most significant predictor of lymphopenia in patients with lung cancer? 🎥 Watch below. #lcsm #NSCLC #SCLC #oncology | @eyubakdemir
The EC strikes first! Liso-cel has been approved for adult patients with relapsed or refractory MCL after ≥ 2 lines of systemic therapy, including a BTK inhibitor. hubs.li/Q03VSQKt0 #lymsm #cancer #oncology
Fertility-sparing surgery had higher rate of recurrence vs complete uterus removal, although the increased rate of recurrence did not affect survival, in patients with early-stage cervical cancer. Read here: hubs.li/Q03VSM930 #gyncsm #oncology #cancer
Cancer cachexia can be deadly, and due to AEs, scientists are now looking at molecular subtypes to inform treatment decisions. Read more about the condition here: hubs.li/Q03VHY-Y0 #cancer #oncology
The EC has granted conditional marketing authorization to SC mosunetuzumab for relapsed/refractory FL following at least 2 prior lines of systemic therapy. hubs.li/Q03VH-Zd0 #lymsm #cancer #oncology
The FDA has approved durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel neoadjuvant and adjuvant treatment, followed by single agent durvalumab as a treatment for patients with resectable gastric and gastroesophageal junction (GEJ) cancers.…
PAS-004 achieved a DCR of 71.4% in patients with BRAF-mutated tumors who had achieved stable disease or PRs; 42.8% (n = 9/21) achieved stable disease or PRs overall. hubs.ly/Q03VHS_90 #oncology #cancer
Eyub Yasar Akdemir, MD, of @BaptistHealthSF spoke with us about proton therapy at #ASTRO25 #cancer #oncology #RadOnc | @eyubakdemir
No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib. hubs.ly/Q03VHQFG0 #NSCLC #lcsm #oncology
Darolutamide + ADT/docetaxel improves efficacy for older patients (75+) with metastatic HSPC, according to the pivotal ARASENS trial subgroup analysis. 📊 Read the findings: hubs.li/Q03VHNMM0 #mHSPC #Oncology #pcsm #ClinicalResearch
The NAPOLI 3 trial demonstrated that NALIRIFOX improved outcomes for patients with metastatic PDAC compared with nab-paclitaxel and gemcitabine. Listen to @DoctorDietrich's thoughts here: hubs.li/Q03Vjws90 #pancsm #oncology #cancer
Stressing the importance of prompt AE disclosure before they become severe ensures that a patient can still undergo resection with curative intent. hubs.li/Q03VjxPW0 #lcsm #cancer #oncology | @DrTomMarron @TischCancer
According to Toru Kondo, PhD, EVA1-ADC may be able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment. hubs.li/Q03VjpTM0 #btsm #glioblastoma #oncology #WorldADC
🚨 NEW EPISODE ALERT! 🚨 ONCOLOGY on the Go in collaboration with @APOSHQ tackles decision-making capacity with Dr. Louis P. Voigt & Dr. Yesne Alici from @MSKCancerCenter. Hosted by Dr. Daniel C. McFarland! 🎧 Listen to the full discussion today: hubs.li/Q03Vjh1W0
The estimated 24-month DFS was 87.1% with adjuvant cemiplimab compared with 64.1% with placebo in patients with CSCC at high risk of recurrence following surgery and radiation. hubs.li/Q03VjbVZ0 #CSCC #cancer #oncology
United States Trends
- 1. #StrangerThings5 251K posts
- 2. Thanksgiving 677K posts
- 3. BYERS 57.4K posts
- 4. robin 93.3K posts
- 5. Reed Sheppard 5,959 posts
- 6. Afghan 289K posts
- 7. holly 64.7K posts
- 8. Dustin 90K posts
- 9. Podz 4,538 posts
- 10. Vecna 59.3K posts
- 11. National Guard 664K posts
- 12. Jonathan 75.4K posts
- 13. hopper 16K posts
- 14. Erica 17.7K posts
- 15. Lucas 83.5K posts
- 16. Nancy 68.6K posts
- 17. Gonzaga 8,532 posts
- 18. noah schnapp 9,007 posts
- 19. Joyce 32.3K posts
- 20. Tini 9,647 posts
You might like
-
The Cancer Letter
@TheCancerLetter -
ACS Journal Cancer
@JournalCancer -
Annals of Oncology
@Annals_Oncology -
OncLive.com
@OncLive -
Oncology Times
@OncologyTimes -
MD Anderson Cancer Center
@MDAndersonNews -
The Oncologist
@OncJournal -
The ASCO Post
@ASCOPost -
JNCI
@JNCI_Now -
Dana-Farber
@DanaFarber -
AACR
@AACR -
Oncology Tube
@oncologytube -
Duke Cancer
@DukeCancer -
Medscape Oncology
@MedscapeOnc -
Journal of Clinical Oncology
@JCO_ASCO
Something went wrong.
Something went wrong.